factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Probable | preserve | 1703-1705 | 1703-1705 | T95 | in | TREATS | 1,703 | 1,705 | preserve | 1635-1644 | 1635-1644 | T90 | ergometry | HealthCareActivity | 1,635 | 1,644 | preserve | 1720-1722 | 1720-1722 | T94 | BP | Finding | 1,720 | 1,722 | A2 | This study indicates that cycle ergometry at 50 and 75% of VO2 Peak elicit similar reductions in post exercise BP. | 1603-1723 | 1,603 | 1,723 | This study indicates that cycle @SUBJECT$ at 50 and 75% of VO2 Peak elicit similar reductions @PREDICAT$ post exercise @OBJECT$ . |
Fact | preserve | 2938-2952 | 2944-2952 | T163 | obese patients | PROCESS_OF | 2,938 | 2,952 | preserve | 2938-2943 | 2938-2943 | T160 | obese | DiseaseOrSyndrome | 2,938 | 2,943 | preserve | 2944-2952 | 2944-2952 | T161 | patients | PatientOrDisabledGroup | 2,944 | 2,952 | A1 | Future studies should incorporate assessment of patient perceived satisfaction with weight loss, health status and quality-of-life evaluations and pharmacoeconomic data to aid clinicians in the decision-making process in terms of weight management of their obese patients. | 2662-2953 | 2,662 | 2,953 | Future studies should incorporate assessment of patient perceived satisfaction with weight loss, health status and quality-of-life evaluations and pharmacoeconomic data to aid clinicians in the decision-making process in terms of weight management of their @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1836-1849 | 1842-1849 | T101 | obese patient | PROCESS_OF | 1,836 | 1,849 | preserve | 1836-1841 | 1836-1841 | T98 | obese | DiseaseOrSyndrome | 1,836 | 1,841 | preserve | 1842-1849 | 1842-1849 | T99 | patient | PatientOrDisabledGroup | 1,842 | 1,849 | A2 | Surgical intervention is reserved for the clinically severe obese patient [body mass index (BMI) > 40 kg/m2]. | 1770-1885 | 1,770 | 1,885 | Surgical intervention is reserved for the clinically severe @SUBJECT$ @PREDICAT$ @OBJECT$ [body mass index (BMI) > 40 kg/m2]. |
Fact | preserve | 1338-1352 | 1344-1352 | T74 | obese patients | PROCESS_OF | 1,338 | 1,352 | preserve | 1338-1343 | 1338-1343 | T70 | obese | DiseaseOrSyndrome | 1,338 | 1,343 | preserve | 1344-1352 | 1344-1352 | T71 | patients | PatientOrDisabledGroup | 1,344 | 1,352 | A4 | There are no long term prospective studies that have demonstrated that weight reduction in obese patients improves survival. | 1240-1371 | 1,240 | 1,371 | There are no long term prospective studies that have demonstrated that weight reduction in @SUBJECT$ @PREDICAT$ @OBJECT$ improves survival. |
Fact | preserve | 1558-1578 | 1570-1578 | T86 | obese patients | PROCESS_OF | 1,558 | 1,578 | preserve | 1558-1563 | 1558-1563 | T82 | obese | DiseaseOrSyndrome | 1,558 | 1,563 | preserve | 1570-1578 | 1570-1578 | T83 | patients | PatientOrDisabledGroup | 1,570 | 1,578 | A5 | However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in obese patients is associated with significant health benefits. | 1372-1626 | 1,372 | 1,626 | However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in @SUBJECT$ @PREDICAT$ @OBJECT$ is associated with significant health benefits. |
Fact | preserve | 1555-1557 | 1555-1557 | T87 | in | PROCESS_OF | 1,555 | 1,557 | preserve | 1526-1542 | 1533-1542 | T81 | weight reduction | Finding | 1,526 | 1,542 | preserve | 1570-1578 | 1570-1578 | T83 | patients | PatientOrDisabledGroup | 1,570 | 1,578 | A10 | However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in obese patients is associated with significant health benefits. | 1372-1626 | 1,372 | 1,626 | However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that @SUBJECT$ of 5 to 10% @PREDICAT$ obese @OBJECT$ is associated with significant health benefits. |
Fact | preserve | 51-54 | 51-54 | T5 | for | TREATS | 51 | 54 | preserve | 32-50 | 41-50 | T3 | surgical treatment | TherapeuticOrPreventiveProcedure | 32 | 50 | preserve | 55-62 | 55-62 | T4 | obesity | DiseaseOrSyndrome | 55 | 62 | A11 | Outcomes of pharmacological and surgical treatment for obesity. | 0-63 | 0 | 63 | Outcomes of pharmacological and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 699-706 | 699-706 | T41 | affects | AFFECTS | 699 | 706 | preserve | 691-698 | 691-698 | T39 | Obesity | DiseaseOrSyndrome | 691 | 698 | preserve | 718-724 | 718-724 | T40 | adults | AgeGroup | 718 | 724 | A13 | Obesity affects 65 million adults in the US. | 691-735 | 691 | 735 | @SUBJECT$ @PREDICAT$ 65 million @OBJECT$ in the US. |
Fact | preserve | 1335-1337 | 1335-1337 | T75 | in | PROCESS_OF | 1,335 | 1,337 | preserve | 1318-1334 | 1325-1334 | T69 | weight reduction | Finding | 1,318 | 1,334 | preserve | 1344-1352 | 1344-1352 | T71 | patients | PatientOrDisabledGroup | 1,344 | 1,352 | A14 | There are no long term prospective studies that have demonstrated that weight reduction in obese patients improves survival. | 1240-1371 | 1,240 | 1,371 | There are no long term prospective studies that have demonstrated that @SUBJECT$ @PREDICAT$ obese @OBJECT$ improves survival. |
Probable | preserve | 673-679 | 673-679 | T45 | relief | TREATS | 673 | 679 | preserve | 639-646 | 639-646 | T36 | surgery | TherapeuticOrPreventiveProcedure | 639 | 646 | preserve | 665-672 | 665-672 | T38 | symptom | SignOrSymptom | 665 | 672 | A3 | Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions. | 463-758 | 463 | 758 | Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary @SUBJECT$ may be better for @OBJECT$ @PREDICAT$ in angina, with fewer hospital admissions and therapeutic interventions. |
Fact | preserve | 795-809 | 802-809 | T55 | vessel disease | LOCATION_OF | 795 | 809 | preserve | 795-801 | 795-801 | T48 | vessel | BodyPartOrganOrOrganComponent | 795 | 801 | preserve | 802-809 | 802-809 | T49 | disease | DiseaseOrSyndrome | 802 | 809 | A4 | Surgery for single- or double-vessel disease is appropriate when initial attempts at revascularization by coronary angioplasty have failed. | 759-910 | 759 | 910 | Surgery for single- or double- @SUBJECT$ @PREDICAT$ @OBJECT$ is appropriate when initial attempts at revascularization by coronary angioplasty have failed. |
Possible | preserve | 1397-1404 | 1397-1404 | T93 | benefit | TREATS | 1,397 | 1,404 | preserve | 1415-1443 | 1426-1443 | T91 | myocardial revascularization | TherapeuticOrPreventiveProcedure | 1,415 | 1,443 | preserve | 1384-1392 | 1384-1392 | T89 | patients | PatientOrDisabledGroup | 1,384 | 1,392 | A5 | Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which patients may benefit most from myocardial revascularization. | 1251-1444 | 1,251 | 1,444 | Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which @OBJECT$ may @PREDICAT$ most from @SUBJECT$ . |
Fact | preserve | 162-166 | 162-166 | T21 | with | PROCESS_OF | 162 | 166 | preserve | 167-183 | 176-183 | T10 | coronary disease | DiseaseOrSyndrome | 167 | 183 | preserve | 154-161 | 154-161 | T9 | elderly | AgeGroup | 154 | 161 | A6 | Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment. | 39-324 | 39 | 324 | Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the @OBJECT$ @PREDICAT$ @SUBJECT$ , in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment. |
Fact | preserve | 96-99 | 96-99 | T19 | for | METHOD_OF | 96 | 99 | preserve | 48-55 | 48-55 | T5 | surgery | TherapeuticOrPreventiveProcedure | 48 | 55 | preserve | 100-132 | 115-132 | T8 | coronary revascularization | TherapeuticOrPreventiveProcedure | 100 | 132 | A10 | Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment. | 39-324 | 39 | 324 | Coronary @SUBJECT$ remains an important therapeutic option @PREDICAT$ @OBJECT$ , particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment. |
Fact | preserve | 969-978 | 969-978 | T71 | treatment | TREATS | 969 | 978 | preserve | 920-927 | 920-927 | T58 | surgery | TherapeuticOrPreventiveProcedure | 920 | 927 | preserve | 982-999 | 994-999 | T62 | cardiogenic shock | PathologicFunction | 982 | 999 | A11 | Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty. | 911-1129 | 911 | 1,129 | Coronary @SUBJECT$ may be a therapeutic option in the @PREDICAT$ of @OBJECT$ , particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty. |
Fact | preserve | 1045-1059 | 1052-1059 | T73 | vessel disease | LOCATION_OF | 1,045 | 1,059 | preserve | 1045-1051 | 1045-1051 | T64 | vessel | BodyPartOrganOrOrganComponent | 1,045 | 1,051 | preserve | 1052-1059 | 1052-1059 | T65 | disease | DiseaseOrSyndrome | 1,052 | 1,059 | A12 | Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty. | 911-1129 | 911 | 1,129 | Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three- @SUBJECT$ @PREDICAT$ @OBJECT$ or the presence of complex lesions not amenable to angioplasty. |
Fact | preserve | 874-876 | 874-876 | T56 | by | METHOD_OF | 874 | 876 | preserve | 877-897 | 886-897 | T54 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 877 | 897 | preserve | 850-867 | 850-867 | T53 | revascularization | TherapeuticOrPreventiveProcedure | 850 | 867 | A15 | Surgery for single- or double-vessel disease is appropriate when initial attempts at revascularization by coronary angioplasty have failed. | 759-910 | 759 | 910 | Surgery for single- or double-vessel disease is appropriate when initial attempts at @OBJECT$ @PREDICAT$ @SUBJECT$ have failed. |
Fact | preserve | 503-512 | 503-512 | T42 | comparing | compared_with | 503 | 512 | preserve | 522-529 | 522-529 | T31 | surgery | TherapeuticOrPreventiveProcedure | 522 | 529 | preserve | 540-560 | 549-560 | T32 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 540 | 560 | A16 | Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions. | 463-758 | 463 | 758 | Interim results from multicenter trials @PREDICAT$ coronary @SUBJECT$ and @OBJECT$ for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions. |
Fact | preserve | 1321-1358 | 1350-1358 | T92 | positron-emission tomography scanning | ISA | 1,321 | 1,358 | preserve | 1321-1349 | 1339-1349 | T87 | positron-emission tomography | DiagnosticProcedure | 1,321 | 1,349 | preserve | 1350-1358 | 1350-1358 | T88 | scanning | DiagnosticProcedure | 1,350 | 1,358 | A17 | Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which patients may benefit most from myocardial revascularization. | 1251-1444 | 1,251 | 1,444 | Recent studies of myocardial viability have examined the use of @SUBJECT$ @PREDICAT$ @OBJECT$ to determine which patients may benefit most from myocardial revascularization. |
Fact | preserve | 1424-1433 | 1424-1433 | T83 | decreased | INHIBITS | 1,424 | 1,433 | preserve | 1418-1423 | 1418-1423 | T72 | ACE-I | PharmacologicSubstance | 1,418 | 1,423 | preserve | 1459-1484 | 1477-1484 | T75 | brain natriuretic peptide | AminoAcidPeptideOrProtein | 1,459 | 1,484 | A1 | Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. | 1399-1600 | 1,399 | 1,600 | Therapy with @SUBJECT$ @PREDICAT$ the levels of Ang II and @OBJECT$ and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. |
Fact | preserve | 1424-1433 | 1424-1433 | T83 | decreased | INHIBITS | 1,424 | 1,433 | preserve | 1418-1423 | 1418-1423 | T72 | ACE-I | PharmacologicSubstance | 1,418 | 1,423 | preserve | 1448-1454 | 1452-1454 | T74 | Ang II | AminoAcidPeptideOrProtein | 1,448 | 1,454 | A2 | Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. | 1399-1600 | 1,399 | 1,600 | Therapy with @SUBJECT$ @PREDICAT$ the levels of @OBJECT$ and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. |
Fact | preserve | 798-804 | 798-804 | T42 | caused | CAUSES | 798 | 804 | preserve | 823-853 | 843-853 | T39 | anterior myocardial infarction | DiseaseOrSyndrome | 823 | 853 | preserve | 773-797 | 790-797 | T37 | congestive heart failure | DiseaseOrSyndrome | 773 | 797 | A3 | We studied 16 patients with congestive heart failure caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD). | 745-927 | 745 | 927 | We studied 16 patients with @OBJECT$ @PREDICAT$ by previous @SUBJECT$ in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD). |
Probable | preserve | 1726-1737 | 1726-1737 | T96 | suppression | INHIBITS | 1,726 | 1,737 | preserve | 1684-1689 | 1684-1689 | T90 | ACE-I | PharmacologicSubstance | 1,684 | 1,689 | preserve | 1719-1725 | 1723-1725 | T93 | Ang II | AminoAcidPeptideOrProtein | 1,719 | 1,725 | A4 | In conclusion, impaired HGF production was restored after the treatment with ACE-I probably by the mechanism of Ang II suppression. | 1601-1738 | 1,601 | 1,738 | In conclusion, impaired HGF production was restored after the treatment with @SUBJECT$ probably by the mechanism of @OBJECT$ @PREDICAT$ . |
Fact | preserve | 987-991 | 987-991 | T55 | with | USES | 987 | 991 | preserve | 977-986 | 977-986 | T45 | treatment | TherapeuticOrPreventiveProcedure | 977 | 986 | preserve | 992-997 | 992-997 | T46 | ACE-I | PharmacologicSubstance | 992 | 997 | A5 | Before and approximately 4 weeks after the treatment with ACE-I, blood samples were collected to measure the levels of HGF, Ang II, and brain natriuretic peptide as a biochemical marker for severity of heart failure. | 928-1163 | 928 | 1,163 | Before and approximately 4 weeks after the @SUBJECT$ @PREDICAT$ @OBJECT$ , blood samples were collected to measure the levels of HGF, Ang II, and brain natriuretic peptide as a biochemical marker for severity of heart failure. |
Fact | preserve | 1285-1289 | 1285-1289 | T70 | with | PROCESS_OF | 1,285 | 1,289 | preserve | 1290-1303 | 1296-1303 | T64 | heart failure | DiseaseOrSyndrome | 1,290 | 1,303 | preserve | 1276-1284 | 1276-1284 | T63 | patients | PatientOrDisabledGroup | 1,276 | 1,284 | A6 | However, in patients with heart failure, HGF response to heparin was significantly attenuated (24+/-5-fold, P<0.05 vs control). | 1264-1398 | 1,264 | 1,398 | However, in @OBJECT$ @PREDICAT$ @SUBJECT$ , HGF response to heparin was significantly attenuated (24+/-5-fold, P<0.05 vs control). |
Fact | preserve | 431-444 | 431-444 | T23 | downregulated | INHIBITS | 431 | 444 | preserve | 448-462 | 448-459 | T21 | angiotensin II | AminoAcidPeptideOrProtein | 448 | 462 | preserve | 413-416 | 413-416 | T19 | HGF | AminoAcidPeptideOrProtein | 413 | 416 | A7 | HGF production is downregulated by angiotensin II (Ang II) in vitro. | 413-487 | 413 | 487 | @OBJECT$ production is @PREDICAT$ by @SUBJECT$ (Ang II) in vitro. |
Possible | preserve | 1816-1818 | 1816-1818 | T104 | in | TREATS | 1,816 | 1,818 | preserve | 1767-1772 | 1767-1772 | T99 | ACE-I | PharmacologicSubstance | 1,767 | 1,772 | preserve | 1819-1827 | 1819-1827 | T101 | patients | PatientOrDisabledGroup | 1,819 | 1,827 | A8 | This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication. | 1739-1911 | 1,739 | 1,911 | This novel effect of @SUBJECT$ may contribute to the clinical improvement @PREDICAT$ @OBJECT$ with heart failure and thereby may have an important therapeutic implication. |
Fact | preserve | 768-772 | 768-772 | T41 | with | PROCESS_OF | 768 | 772 | preserve | 773-797 | 790-797 | T37 | congestive heart failure | DiseaseOrSyndrome | 773 | 797 | preserve | 759-767 | 759-767 | T36 | patients | PatientOrDisabledGroup | 759 | 767 | A9 | We studied 16 patients with congestive heart failure caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD). | 745-927 | 745 | 927 | We studied 16 @OBJECT$ @PREDICAT$ @SUBJECT$ caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD). |
Fact | preserve | 576-578 | 576-578 | T35 | in | TREATS | 576 | 578 | preserve | 569-575 | 573-575 | T28 | Ang II | AminoAcidPeptideOrProtein | 569 | 575 | preserve | 579-587 | 579-587 | T29 | patients | PatientOrDisabledGroup | 579 | 587 | A10 | We hypothesized that HGF production is impaired as the result of increased Ang II in patients with congestive heart failure, and that if so, the impaired production should be restored with angiotensin-converting enzyme inhibitors (ACE-I). | 488-744 | 488 | 744 | We hypothesized that HGF production is impaired as the result of increased @SUBJECT$ @PREDICAT$ @OBJECT$ with congestive heart failure, and that if so, the impaired production should be restored with angiotensin-converting enzyme inhibitors (ACE-I). |
Fact | preserve | 194-198 | 194-198 | T10 | with | PROCESS_OF | 194 | 198 | preserve | 199-230 | 223-230 | T9 | congestive heart failure | DiseaseOrSyndrome | 199 | 230 | preserve | 185-193 | 185-193 | T8 | patients | PatientOrDisabledGroup | 185 | 193 | A11 | Endothelium-dependent vasodilation is impaired in patients with congestive heart failure. | 135-231 | 135 | 231 | Endothelium-dependent vasodilation is impaired in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Possible | preserve | 1816-1818 | 1816-1818 | T104 | in | TREATS | 1,816 | 1,818 | preserve | 1767-1772 | 1767-1772 | T99 | ACE-I | PharmacologicSubstance | 1,767 | 1,772 | preserve | 1833-1852 | 1845-1852 | T102 | heart failure | DiseaseOrSyndrome | 1,833 | 1,852 | A12 | This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication. | 1739-1911 | 1,739 | 1,911 | This novel effect of @SUBJECT$ may contribute to the clinical improvement @PREDICAT$ patients with @OBJECT$ and thereby may have an important therapeutic implication. |
Fact | preserve | 1413-1417 | 1413-1417 | T82 | with | USES | 1,413 | 1,417 | preserve | 1399-1406 | 1399-1406 | T71 | Therapy | TherapeuticOrPreventiveProcedure | 1,399 | 1,406 | preserve | 1418-1423 | 1418-1423 | T72 | ACE-I | PharmacologicSubstance | 1,418 | 1,423 | A13 | Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. | 1399-1600 | 1,399 | 1,600 | @SUBJECT$ @PREDICAT$ @OBJECT$ decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response. |
Fact | preserve | 258-348 | 289-291 | T18 | hepatocyte growth factor (HGF) is one of the most potent and specific growth factors | ISA | 258 | 348 | preserve | 258-282 | 276-282 | T12 | hepatocyte growth factor | AminoAcidPeptideOrProtein | 258 | 282 | preserve | 334-348 | 341-348 | T16 | growth factors | BiologicallyActiveSubstance | 334 | 348 | A16 | For vascular endothelium, hepatocyte growth factor (HGF) is one of the most potent and specific growth factors, which acts protectively against endothelial dysfunction. | 232-412 | 232 | 412 | For vascular endothelium, @SUBJECT$ @PREDICAT$ @OBJECT$ , which acts protectively against endothelial dysfunction. |
Fact | preserve | 1216-1225 | 1216-1225 | T62 | increased | STIMULATES | 1,216 | 1,225 | preserve | 1208-1215 | 1208-1215 | T58 | heparin | BiologicallyActiveSubstance | 1,208 | 1,215 | preserve | 1226-1229 | 1226-1229 | T59 | HGF | AminoAcidPeptideOrProtein | 1,226 | 1,229 | A17 | We also studied 5 control subjects, in whom heparin increased HGF production to 48+/-5-fold. | 1164-1263 | 1,164 | 1,263 | We also studied 5 control subjects, in whom @SUBJECT$ @PREDICAT$ @OBJECT$ production to 48+/-5-fold. |
Fact | preserve | 1828-1832 | 1828-1832 | T105 | with | PROCESS_OF | 1,828 | 1,832 | preserve | 1833-1852 | 1845-1852 | T102 | heart failure | DiseaseOrSyndrome | 1,833 | 1,852 | preserve | 1819-1827 | 1819-1827 | T101 | patients | PatientOrDisabledGroup | 1,819 | 1,827 | A19 | This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication. | 1739-1911 | 1,739 | 1,911 | This novel effect of ACE-I may contribute to the clinical improvement in @OBJECT$ @PREDICAT$ @SUBJECT$ and thereby may have an important therapeutic implication. |
Fact | preserve | 1679-1683 | 1679-1683 | T95 | with | USES | 1,679 | 1,683 | preserve | 1669-1678 | 1669-1678 | T89 | treatment | TherapeuticOrPreventiveProcedure | 1,669 | 1,678 | preserve | 1684-1689 | 1684-1689 | T90 | ACE-I | PharmacologicSubstance | 1,684 | 1,689 | A20 | In conclusion, impaired HGF production was restored after the treatment with ACE-I probably by the mechanism of Ang II suppression. | 1601-1738 | 1,601 | 1,738 | In conclusion, impaired HGF production was restored after the @SUBJECT$ @PREDICAT$ @OBJECT$ probably by the mechanism of Ang II suppression. |
Fact | preserve | 1670-1684 | 1678-1684 | T86 | elderly people | PROCESS_OF | 1,670 | 1,684 | preserve | 1697-1716 | 1704-1716 | T80 | atrial fibrillation | PathologicFunction | 1,697 | 1,716 | preserve | 1670-1677 | 1670-1677 | T78 | elderly | AgeGroup | 1,670 | 1,677 | A1 | CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke. | 1652-1758 | 1,652 | 1,758 | CONCLUSIONS: Most @OBJECT$ @PREDICAT$ with @SUBJECT$ would accept treatment to prevent stroke. |
Fact | preserve | 1065-1079 | 1073-1079 | T55 | elderly people | PROCESS_OF | 1,065 | 1,079 | preserve | 1085-1104 | 1092-1104 | T52 | atrial fibrillation | PathologicFunction | 1,085 | 1,104 | preserve | 1065-1072 | 1065-1072 | T50 | elderly | AgeGroup | 1,065 | 1,072 | A2 | RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified. | 1034-1127 | 1,034 | 1,127 | RESULTS: Two hundred and seven @OBJECT$ @PREDICAT$ with @SUBJECT$ were identified. |
Fact | preserve | 1204-1211 | 1204-1211 | T64 | prevent | PREVENTS | 1,204 | 1,211 | preserve | 1185-1194 | 1185-1194 | T58 | treatment | TherapeuticOrPreventiveProcedure | 1,185 | 1,194 | preserve | 1212-1218 | 1212-1218 | T59 | stroke | DiseaseOrSyndrome | 1,212 | 1,218 | A3 | Almost all subjects expressed a willingness to undertake treatment to prevent stroke and preferred blood testing performed outside of hospital. | 1128-1277 | 1,128 | 1,277 | Almost all subjects expressed a willingness to undertake @SUBJECT$ to @PREDICAT$ @OBJECT$ and preferred blood testing performed outside of hospital. |
Fact | preserve | 410-414 | 410-414 | T23 | with | PROCESS_OF | 410 | 414 | preserve | 415-434 | 422-434 | T20 | atrial fibrillation | PathologicFunction | 415 | 434 | preserve | 402-409 | 402-409 | T19 | elderly | AgeGroup | 402 | 409 | A4 | AIM: To investigate the prevalence of disability, cognitive impairment, and problems with compliance in a representative sample of the elderly with atrial fibrillation, and to determine whether they would want treatment and how they would like services to be arranged. | 254-547 | 254 | 547 | AIM: To investigate the prevalence of disability, cognitive impairment, and problems with compliance in a representative sample of the @OBJECT$ @PREDICAT$ @SUBJECT$ , and to determine whether they would want treatment and how they would like services to be arranged. |
Fact | preserve | 1685-1689 | 1685-1689 | T84 | with | PROCESS_OF | 1,685 | 1,689 | preserve | 1697-1716 | 1704-1716 | T80 | atrial fibrillation | PathologicFunction | 1,697 | 1,716 | preserve | 1678-1684 | 1678-1684 | T79 | people | PopulationGroup | 1,678 | 1,684 | A5 | CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke. | 1652-1758 | 1,652 | 1,758 | CONCLUSIONS: Most elderly @OBJECT$ @PREDICAT$ @SUBJECT$ would accept treatment to prevent stroke. |
Fact | preserve | 1080-1084 | 1080-1084 | T54 | with | PROCESS_OF | 1,080 | 1,084 | preserve | 1085-1104 | 1092-1104 | T52 | atrial fibrillation | PathologicFunction | 1,085 | 1,104 | preserve | 1073-1079 | 1073-1079 | T51 | people | PopulationGroup | 1,073 | 1,079 | A6 | RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified. | 1034-1127 | 1,034 | 1,127 | RESULTS: Two hundred and seven elderly @OBJECT$ @PREDICAT$ @SUBJECT$ were identified. |
Fact | preserve | 1065-1079 | 1073-1079 | T53 | elderly people | ISA | 1,065 | 1,079 | preserve | 1065-1072 | 1065-1072 | T50 | elderly | AgeGroup | 1,065 | 1,072 | preserve | 1073-1079 | 1073-1079 | T51 | people | PopulationGroup | 1,073 | 1,079 | A7 | RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified. | 1034-1127 | 1,034 | 1,127 | RESULTS: Two hundred and seven @SUBJECT$ @PREDICAT$ @OBJECT$ with atrial fibrillation were identified. |
Fact | preserve | 1743-1750 | 1743-1750 | T85 | prevent | PREVENTS | 1,743 | 1,750 | preserve | 1730-1739 | 1730-1739 | T81 | treatment | TherapeuticOrPreventiveProcedure | 1,730 | 1,739 | preserve | 1751-1757 | 1751-1757 | T82 | stroke | DiseaseOrSyndrome | 1,751 | 1,757 | A9 | CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke. | 1652-1758 | 1,652 | 1,758 | CONCLUSIONS: Most elderly people with atrial fibrillation would accept @SUBJECT$ to @PREDICAT$ @OBJECT$ . |
Fact | preserve | 31-35 | 31-35 | T7 | with | PROCESS_OF | 31 | 35 | preserve | 36-55 | 43-55 | T3 | atrial fibrillation | PathologicFunction | 36 | 55 | preserve | 22-30 | 22-30 | T2 | patients | PatientOrDisabledGroup | 22 | 30 | A10 | A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. | 0-114 | 0 | 114 | A community survey of @OBJECT$ @PREDICAT$ @SUBJECT$ : associated disabilities and treatment preferences. |
Fact | preserve | 1670-1684 | 1678-1684 | T83 | elderly people | ISA | 1,670 | 1,684 | preserve | 1670-1677 | 1670-1677 | T78 | elderly | AgeGroup | 1,670 | 1,677 | preserve | 1678-1684 | 1678-1684 | T79 | people | PopulationGroup | 1,678 | 1,684 | A12 | CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke. | 1652-1758 | 1,652 | 1,758 | CONCLUSIONS: Most @SUBJECT$ @PREDICAT$ @OBJECT$ with atrial fibrillation would accept treatment to prevent stroke. |
Fact | preserve | 626-630 | 626-630 | T31 | with | PROCESS_OF | 626 | 630 | preserve | 631-650 | 638-650 | T29 | atrial fibrillation | PathologicFunction | 631 | 650 | preserve | 595-602 | 595-602 | T27 | elderly | AgeGroup | 595 | 602 | A13 | METHOD: In a survey of a random sample of 4843 elderly subjects, those with atrial fibrillation were identified using electrocardiograms. | 548-692 | 548 | 692 | METHOD: In a survey of a random sample of 4843 @OBJECT$ subjects, those @PREDICAT$ @SUBJECT$ were identified using electrocardiograms. |
Fact | preserve | 1594-1605 | 1594-1605 | T86 | predisposes | PREDISPOSES | 1,594 | 1,605 | preserve | 1571-1588 | 1580-1588 | T83 | motility disorder | PathologicFunction | 1,571 | 1,588 | preserve | 1629-1638 | 1629-1638 | T84 | dysphagia | DiseaseOrSyndrome | 1,629 | 1,638 | A2 | When performed prior to fundoplication, it appears to be of significant value in detecting a subtle functional motility disorder that predisposes to postoperative dysphagia. | 1453-1639 | 1,453 | 1,639 | When performed prior to fundoplication, it appears to be of significant value in detecting a subtle functional @SUBJECT$ that @PREDICAT$ to postoperative @OBJECT$ . |
Fact | preserve | 327-331 | 327-331 | T21 | have | PROCESS_OF | 327 | 331 | preserve | 343-371 | 360-371 | T19 | esophageal dysmotility | DiseaseOrSyndrome | 343 | 371 | preserve | 302-310 | 302-310 | T16 | patients | PatientOrDisabledGroup | 302 | 310 | A3 | This is more likely in those patients with reflux who have concurrent esophageal dysmotility. | 266-372 | 266 | 372 | This is more likely in those @OBJECT$ with reflux who @PREDICAT$ concurrent @SUBJECT$ . |
Counterfact | preserve | 1245-1248 | 1245-1248 | T75 | had | PROCESS_OF | 1,245 | 1,248 | preserve | 1252-1261 | 1252-1261 | T68 | dysphagia | DiseaseOrSyndrome | 1,252 | 1,261 | preserve | 1232-1240 | 1232-1240 | T67 | patients | PatientOrDisabledGroup | 1,232 | 1,240 | A4 | Of the 21 patients who had no dysphagia after surgery, 20 patients had normal preoperative jello esophageal transit, showing a specificity of 95%. | 1222-1381 | 1,222 | 1,381 | Of the 21 @OBJECT$ who @PREDICAT$ no @SUBJECT$ after surgery, 20 patients had normal preoperative jello esophageal transit, showing a specificity of 95%. |
Fact | preserve | 129-132 | 129-132 | T12 | for | TREATS | 129 | 132 | preserve | 104-118 | 104-118 | T6 | Fundoplication | TherapeuticOrPreventiveProcedure | 104 | 118 | preserve | 133-164 | 157-164 | T7 | gastroesophageal reflux disease | DiseaseOrSyndrome | 133 | 164 | A7 | Fundoplication performed for gastroesophageal reflux disease may be complicated by postoperative dysphagia despite successful reduction in reflux symptoms. | 104-265 | 104 | 265 | @SUBJECT$ performed @PREDICAT$ @OBJECT$ may be complicated by postoperative dysphagia despite successful reduction in reflux symptoms. |
Fact | preserve | 311-315 | 311-315 | T20 | with | PROCESS_OF | 311 | 315 | preserve | 316-322 | 316-322 | T17 | reflux | PathologicFunction | 316 | 322 | preserve | 302-310 | 302-310 | T16 | patients | PatientOrDisabledGroup | 302 | 310 | A8 | This is more likely in those patients with reflux who have concurrent esophageal dysmotility. | 266-372 | 266 | 372 | This is more likely in those @OBJECT$ @PREDICAT$ @SUBJECT$ who have concurrent esophageal dysmotility. |
Fact | preserve | 1085-1088 | 1085-1088 | T65 | had | PROCESS_OF | 1,085 | 1,088 | preserve | 1089-1098 | 1089-1098 | T58 | dysphagia | DiseaseOrSyndrome | 1,089 | 1,098 | preserve | 1076-1084 | 1076-1084 | T57 | patients | PatientOrDisabledGroup | 1,076 | 1,084 | A9 | Six months after surgery, five patients had dysphagia and of these four were found to have abnormal preoperative jello esophageal transit, for a sensitivity of 80%. | 1045-1221 | 1,045 | 1,221 | Six months after surgery, five @OBJECT$ @PREDICAT$ @SUBJECT$ and of these four were found to have abnormal preoperative jello esophageal transit, for a sensitivity of 80%. |
Fact | preserve | 829-852 | 840-852 | T48 | intestinal side-effects | LOCATION_OF | 829 | 852 | preserve | 829-839 | 829-839 | T42 | intestinal | BodyPartOrganOrOrganComponent | 829 | 839 | preserve | 840-852 | 840-852 | T43 | side-effects | PathologicFunction | 840 | 852 | A1 | Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance. | 766-961 | 766 | 961 | Because of its mechanism of action, this drug can induce @SUBJECT$ @PREDICAT$ @OBJECT$ which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance. |
Probable | preserve | 822-828 | 822-828 | T47 | induce | CAUSES | 822 | 828 | preserve | 807-811 | 807-811 | T41 | drug | PharmacologicSubstance | 807 | 811 | preserve | 840-852 | 840-852 | T43 | side-effects | PathologicFunction | 840 | 852 | A4 | Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance. | 766-961 | 766 | 961 | Because of its mechanism of action, this @SUBJECT$ can @PREDICAT$ intestinal @OBJECT$ which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance. |
Fact | preserve | 1954-1958 | 1954-1958 | T124 | with | PROCESS_OF | 1,954 | 1,958 | preserve | 1959-1993 | 1982-1993 | T110 | left ventricular enlargement | PathologicFunction | 1,959 | 1,993 | preserve | 1945-1953 | 1945-1953 | T109 | Patients | PatientOrDisabledGroup | 1,945 | 1,953 | A1 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. | 1945-2124 | 1,945 | 2,124 | @OBJECT$ @PREDICAT$ @SUBJECT$ and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. |
Fact | preserve | 1909-1913 | 1909-1913 | T108 | with | PROCESS_OF | 1,909 | 1,913 | preserve | 1926-1943 | 1935-1943 | T107 | cerebral ischemia | DiseaseOrSyndrome | 1,926 | 1,943 | preserve | 1900-1908 | 1900-1908 | T106 | patients | PatientOrDisabledGroup | 1,900 | 1,908 | A2 | CONCLUSION: Abnormalities are commonly found by TEE in patients with unexplained cerebral ischemia. | 1839-1944 | 1,839 | 1,944 | CONCLUSION: Abnormalities are commonly found by TEE in @OBJECT$ @PREDICAT$ unexplained @SUBJECT$ . |
Probable | preserve | 2194-2196 | 2194-2196 | T134 | in | TREATS | 2,194 | 2,196 | preserve | 2161-2176 | 2161-2176 | T130 | anticoagulation | TherapeuticOrPreventiveProcedure | 2,161 | 2,176 | preserve | 2211-2217 | 2211-2217 | T132 | stroke | DiseaseOrSyndrome | 2,211 | 2,217 | A3 | Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease. | 2125-2271 | 2,125 | 2,271 | Empiric therapy with systemic @SUBJECT$ may be indicated @PREDICAT$ patients with @OBJECT$ unexplained by carotid atherosclerotic disease. |
Fact | preserve | 1689-1698 | 1689-1698 | T101 | receiving | ADMINISTERED_TO | 1,689 | 1,698 | preserve | 1699-1706 | 1699-1706 | T92 | aspirin | OrganicChemical | 1,699 | 1,706 | preserve | 1680-1688 | 1680-1688 | T91 | patients | PatientOrDisabledGroup | 1,680 | 1,688 | A5 | Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque. | 1674-1838 | 1,674 | 1,838 | Among @OBJECT$ @PREDICAT$ @SUBJECT$ , a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque. |
Fact | preserve | 2102-2117 | 2110-2117 | T126 | aspirin therapy | USES | 2,102 | 2,117 | preserve | 2110-2117 | 2110-2117 | T122 | therapy | TherapeuticOrPreventiveProcedure | 2,110 | 2,117 | preserve | 2102-2109 | 2102-2109 | T121 | aspirin | OrganicChemical | 2,102 | 2,109 | A6 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. | 1945-2124 | 1,945 | 2,124 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving @OBJECT$ @PREDICAT$ @SUBJECT$ alone. |
Fact | preserve | 1755-1757 | 1755-1757 | T102 | in | COEXISTS_WITH | 1,755 | 1,757 | preserve | 1733-1739 | 1733-1739 | T95 | stroke | DiseaseOrSyndrome | 1,733 | 1,739 | preserve | 1808-1837 | 1831-1837 | T100 | atherosclerotic aortic plaque | AcquiredAbnormality | 1,808 | 1,837 | A7 | Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque. | 1674-1838 | 1,674 | 1,838 | Among patients receiving aspirin, a higher recurrent @SUBJECT$ rate was noted @PREDICAT$ those with left ventricular enlargement and @OBJECT$ . |
Fact | preserve | 1325-1341 | 1334-1341 | T71 | warfarin therapy | ISA | 1,325 | 1,341 | preserve | 1325-1333 | 1325-1333 | T69 | warfarin | HazardousOrPoisonousSubstance | 1,325 | 1,333 | preserve | 1334-1341 | 1334-1341 | T70 | therapy | TherapeuticOrPreventiveProcedure | 1,334 | 1,341 | A8 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02). | 1175-1351 | 1,175 | 1,351 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving @SUBJECT$ @PREDICAT$ @OBJECT$ (P <.02). |
Fact | preserve | 1325-1341 | 1334-1341 | T74 | warfarin therapy | ADMINISTERED_TO | 1,325 | 1,341 | preserve | 1325-1333 | 1325-1333 | T69 | warfarin | HazardousOrPoisonousSubstance | 1,325 | 1,333 | preserve | 1306-1314 | 1306-1314 | T68 | patients | PatientOrDisabledGroup | 1,306 | 1,314 | A10 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02). | 1175-1351 | 1,175 | 1,351 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the @OBJECT$ receiving @SUBJECT$ @PREDICAT$ (P <.02). |
Fact | preserve | 1325-1341 | 1334-1341 | T73 | warfarin therapy | USES | 1,325 | 1,341 | preserve | 1334-1341 | 1334-1341 | T70 | therapy | TherapeuticOrPreventiveProcedure | 1,334 | 1,341 | preserve | 1325-1333 | 1325-1333 | T69 | warfarin | HazardousOrPoisonousSubstance | 1,325 | 1,333 | A11 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02). | 1175-1351 | 1,175 | 1,351 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving @OBJECT$ @PREDICAT$ @SUBJECT$ (P <.02). |
Fact | preserve | 2206-2210 | 2206-2210 | T135 | with | PROCESS_OF | 2,206 | 2,210 | preserve | 2211-2217 | 2211-2217 | T132 | stroke | DiseaseOrSyndrome | 2,211 | 2,217 | preserve | 2197-2205 | 2197-2205 | T131 | patients | PatientOrDisabledGroup | 2,197 | 2,205 | A13 | Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease. | 2125-2271 | 2,125 | 2,271 | Empiric therapy with systemic anticoagulation may be indicated in @OBJECT$ @PREDICAT$ @SUBJECT$ unexplained by carotid atherosclerotic disease. |
Fact | preserve | 1824-1837 | 1831-1837 | T104 | aortic plaque | LOCATION_OF | 1,824 | 1,837 | preserve | 1824-1830 | 1824-1830 | T99 | aortic | BodyPartOrganOrOrganComponent | 1,824 | 1,830 | preserve | 1808-1837 | 1831-1837 | T100 | atherosclerotic aortic plaque | AcquiredAbnormality | 1,808 | 1,837 | A14 | Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque. | 1674-1838 | 1,674 | 1,838 | Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 347-351 | 347-351 | T16 | with | PROCESS_OF | 347 | 351 | preserve | 364-381 | 373-381 | T15 | cerebral ischemia | DiseaseOrSyndrome | 364 | 381 | preserve | 338-346 | 338-346 | T14 | patients | PatientOrDisabledGroup | 338 | 346 | A15 | BACKGROUND: Transesophageal echocardiography (TEE) continues to play a prominent role in the evaluation of patients with unexplained cerebral ischemia. | 224-382 | 224 | 382 | BACKGROUND: Transesophageal echocardiography (TEE) continues to play a prominent role in the evaluation of @OBJECT$ @PREDICAT$ unexplained @SUBJECT$ . |
Fact | preserve | 2102-2117 | 2110-2117 | T123 | aspirin therapy | ISA | 2,102 | 2,117 | preserve | 2102-2109 | 2102-2109 | T121 | aspirin | OrganicChemical | 2,102 | 2,109 | preserve | 2110-2117 | 2110-2117 | T122 | therapy | TherapeuticOrPreventiveProcedure | 2,110 | 2,117 | A16 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. | 1945-2124 | 1,945 | 2,124 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving @SUBJECT$ @PREDICAT$ @OBJECT$ alone. |
Fact | preserve | 1755-1757 | 1755-1757 | T102 | in | COEXISTS_WITH | 1,755 | 1,757 | preserve | 1733-1739 | 1733-1739 | T95 | stroke | DiseaseOrSyndrome | 1,733 | 1,739 | preserve | 1769-1797 | 1786-1797 | T98 | left ventricular enlargement | PathologicFunction | 1,769 | 1,797 | A18 | Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque. | 1674-1838 | 1,674 | 1,838 | Among patients receiving aspirin, a higher recurrent @SUBJECT$ rate was noted @PREDICAT$ those with @OBJECT$ and atherosclerotic aortic plaque. |
Fact | preserve | 1315-1324 | 1315-1324 | T72 | receiving | ADMINISTERED_TO | 1,315 | 1,324 | preserve | 1334-1341 | 1334-1341 | T70 | therapy | TherapeuticOrPreventiveProcedure | 1,334 | 1,341 | preserve | 1306-1314 | 1306-1314 | T68 | patients | PatientOrDisabledGroup | 1,306 | 1,314 | A19 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02). | 1175-1351 | 1,175 | 1,351 | RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the @OBJECT$ @PREDICAT$ warfarin @SUBJECT$ (P <.02). |
Probable | preserve | 2194-2196 | 2194-2196 | T134 | in | TREATS | 2,194 | 2,196 | preserve | 2161-2176 | 2161-2176 | T130 | anticoagulation | TherapeuticOrPreventiveProcedure | 2,161 | 2,176 | preserve | 2197-2205 | 2197-2205 | T131 | patients | PatientOrDisabledGroup | 2,197 | 2,205 | A20 | Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease. | 2125-2271 | 2,125 | 2,271 | Empiric therapy with systemic @SUBJECT$ may be indicated @PREDICAT$ @OBJECT$ with stroke unexplained by carotid atherosclerotic disease. |
Fact | preserve | 2011-2024 | 2018-2024 | T125 | aortic plaque | LOCATION_OF | 2,011 | 2,024 | preserve | 2011-2017 | 2011-2017 | T112 | aortic | BodyPartOrganOrOrganComponent | 2,011 | 2,017 | preserve | 2018-2024 | 2018-2024 | T113 | plaque | AcquiredAbnormality | 2,018 | 2,024 | A21 | Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. | 1945-2124 | 1,945 | 2,124 | Patients with left ventricular enlargement and demonstrable @SUBJECT$ @PREDICAT$ @OBJECT$ on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone. |
Fact | preserve | 472-493 | 485-493 | T30 | hypertensive patients | PROCESS_OF | 472 | 493 | preserve | 472-484 | 472-484 | T28 | hypertensive | Finding | 472 | 484 | preserve | 485-493 | 485-493 | T29 | patients | PatientOrDisabledGroup | 485 | 493 | A1 | 3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients. | 384-494 | 384 | 494 | 3 days after discontinuing therapy in previously well-controlled mild to moderate @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Uncommitted | preserve | 419-421 | 419-421 | T31 | in | TREATS | 419 | 421 | preserve | 411-418 | 411-418 | T24 | therapy | TherapeuticOrPreventiveProcedure | 411 | 418 | preserve | 472-484 | 472-484 | T28 | hypertensive | Finding | 472 | 484 | A3 | 3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients. | 384-494 | 384 | 494 | 3 days after discontinuing @SUBJECT$ @PREDICAT$ previously well-controlled mild to moderate @OBJECT$ patients. |
Fact | preserve | 224-233 | 224-233 | T15 | treatment | TREATS | 224 | 233 | preserve | 116-134 | 124-134 | T8 | calcium antagonist | PharmacologicSubstance | 116 | 134 | preserve | 237-249 | 237-249 | T13 | hypertension | DiseaseOrSyndrome | 237 | 249 | A4 | Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension. | 100-250 | 100 | 250 | Amlodipine is a @SUBJECT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 100-134 | 124-134 | T14 | Amlodipine is a calcium antagonist | ISA | 100 | 134 | preserve | 100-110 | 100-110 | T7 | Amlodipine | OrganicChemical | 100 | 110 | preserve | 116-134 | 124-134 | T8 | calcium antagonist | PharmacologicSubstance | 116 | 134 | A5 | Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension. | 100-250 | 100 | 250 | @SUBJECT$ @PREDICAT$ @OBJECT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension. |
Fact | preserve | 100-134 | 124-134 | T16 | Amlodipine is a calcium antagonist | TREATS | 100 | 134 | preserve | 100-110 | 100-110 | T7 | Amlodipine | OrganicChemical | 100 | 110 | preserve | 237-249 | 237-249 | T13 | hypertension | DiseaseOrSyndrome | 237 | 249 | A6 | Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension. | 100-250 | 100 | 250 | @SUBJECT$ @PREDICAT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of @OBJECT$ . |
Uncommitted | preserve | 419-421 | 419-421 | T31 | in | TREATS | 419 | 421 | preserve | 411-418 | 411-418 | T24 | therapy | TherapeuticOrPreventiveProcedure | 411 | 418 | preserve | 485-493 | 485-493 | T29 | patients | PatientOrDisabledGroup | 485 | 493 | A7 | 3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients. | 384-494 | 384 | 494 | 3 days after discontinuing @SUBJECT$ @PREDICAT$ previously well-controlled mild to moderate hypertensive @OBJECT$ . |
Fact | preserve | 1635-1659 | 1650-1659 | T90 | cyclooxygenase enzymatic | ASSOCIATED_WITH | 1,635 | 1,659 | preserve | 1635-1649 | 1635-1649 | T77 | cyclooxygenase | AminoAcidPeptideOrProtein | 1,635 | 1,649 | preserve | 1690-1702 | 1690-1702 | T81 | hypertension | DiseaseOrSyndrome | 1,690 | 1,702 | A1 | CONCLUSIONS: Nonselective inhibition of the cyclooxygenase enzymatic system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency. | 1585-1787 | 1,585 | 1,787 | CONCLUSIONS: Nonselective inhibition of the @SUBJECT$ @PREDICAT$ system does not influence the @OBJECT$ seen in the rat preeclampsia model induced by chronic nitric oxide deficiency. |
Probable | preserve | 1842-1850 | 1842-1850 | T95 | reversed | TREATS | 1,842 | 1,850 | preserve | 1856-1868 | 1856-1868 | T93 | prostacyclin | BiologicallyActiveSubstance | 1,856 | 1,868 | preserve | 1798-1810 | 1798-1810 | T91 | hypertension | DiseaseOrSyndrome | 1,798 | 1,810 | A2 | The hypertension in this model can be partially reversed with prostacyclin analogs. | 1788-1877 | 1,788 | 1,877 | The @OBJECT$ in this model can be partially @PREDICAT$ with @SUBJECT$ analogs. |
Fact | preserve | 1346-1353 | 1346-1353 | T69 | induced | CAUSES | 1,346 | 1,353 | preserve | 1378-1399 | 1394-1399 | T67 | arginine methyl ester | AminoAcidPeptideOrProtein | 1,378 | 1,399 | preserve | 1333-1345 | 1333-1345 | T66 | hypertension | DiseaseOrSyndrome | 1,333 | 1,345 | A3 | RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the hypertension induced by N G -nitro- L -arginine methyl ester. | 1210-1400 | 1,210 | 1,400 | RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the @OBJECT$ @PREDICAT$ by N G -nitro- L - @SUBJECT$ . |
Fact | preserve | 1635-1659 | 1650-1659 | T88 | cyclooxygenase enzymatic | ISA | 1,635 | 1,659 | preserve | 1635-1649 | 1635-1649 | T77 | cyclooxygenase | AminoAcidPeptideOrProtein | 1,635 | 1,649 | preserve | 1650-1659 | 1650-1659 | T78 | enzymatic | Enzyme | 1,650 | 1,659 | A5 | CONCLUSIONS: Nonselective inhibition of the cyclooxygenase enzymatic system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency. | 1585-1787 | 1,585 | 1,787 | CONCLUSIONS: Nonselective inhibition of the @SUBJECT$ @PREDICAT$ @OBJECT$ system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency. |
Counterfact | preserve | 1319-1325 | 1319-1325 | T68 | effect | AFFECTS | 1,319 | 1,325 | preserve | 1287-1299 | 1287-1299 | T63 | indomethacin | OrganicChemical | 1,287 | 1,299 | preserve | 1333-1345 | 1333-1345 | T66 | hypertension | DiseaseOrSyndrome | 1,333 | 1,345 | A8 | RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the hypertension induced by N G -nitro- L -arginine methyl ester. | 1210-1400 | 1,210 | 1,400 | RESULTS: Except for an increase on the day after insertion of the pump @SUBJECT$ had no significant @PREDICAT$ on the @OBJECT$ induced by N G -nitro- L -arginine methyl ester. |
Fact | preserve | 1489-1491 | 1489-1491 | T76 | in | TREATS | 1,489 | 1,491 | preserve | 1419-1427 | 1419-1427 | T71 | agonists | PharmacologicSubstance | 1,419 | 1,427 | preserve | 1492-1506 | 1498-1506 | T74 | blood pressure | Finding | 1,492 | 1,506 | A9 | Both prostacyclin agonists (iloprost and cicaprost), however, attenuated the rise in blood pressure usually seen after N G -nitro- L -arginine methyl ester administration. | 1401-1584 | 1,401 | 1,584 | Both prostacyclin @SUBJECT$ (iloprost and cicaprost), however, attenuated the rise @PREDICAT$ @OBJECT$ usually seen after N G -nitro- L -arginine methyl ester administration. |
Fact | preserve | 2202-2222 | 2214-2222 | T147 | obese patients | PROCESS_OF | 2,202 | 2,222 | preserve | 2202-2207 | 2202-2207 | T135 | obese | DiseaseOrSyndrome | 2,202 | 2,207 | preserve | 2214-2222 | 2214-2222 | T136 | patients | PatientOrDisabledGroup | 2,214 | 2,222 | A2 | Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity. | 1973-2377 | 1,973 | 2,377 | Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in @SUBJECT$ @PREDICAT$ @OBJECT$ ; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity. |
Fact | preserve | 1612-1614 | 1612-1614 | T96 | in | ASSOCIATED_WITH | 1,612 | 1,614 | preserve | 1519-1526 | 1519-1526 | T89 | IGFBP-3 | AminoAcidPeptideOrProtein | 1,519 | 1,526 | preserve | 1621-1628 | 1621-1628 | T95 | obesity | DiseaseOrSyndrome | 1,621 | 1,628 | A3 | As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have been described in obesity. | 1340-1629 | 1,340 | 1,629 | As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high @SUBJECT$ and increased GH binding protein (GHBP) circulating levels have been described @PREDICAT$ @OBJECT$ . |
Fact | preserve | 900-902 | 900-902 | T52 | in | ASSOCIATED_WITH | 900 | 902 | preserve | 895-899 | 895-899 | T50 | GHRH | AminoAcidPeptideOrProtein | 895 | 899 | preserve | 903-910 | 903-910 | T51 | obesity | DiseaseOrSyndrome | 903 | 910 | A6 | Compounds thought to inhibit hypothalamic somatostatin (SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the somatotropin response to GHRH in obesity. | 685-911 | 685 | 911 | Compounds thought to inhibit hypothalamic somatostatin (SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the somatotropin response to @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 3195-3199 | 3195-3199 | T201 | with | USES | 3,195 | 3,199 | preserve | 3185-3194 | 3185-3194 | T191 | treatment | TherapeuticOrPreventiveProcedure | 3,185 | 3,194 | preserve | 3213-3215 | 3213-3215 | T192 | GH | AminoAcidPeptideOrProtein | 3,213 | 3,215 | A8 | In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction. | 3167-3388 | 3,167 | 3,388 | In spite of this, @SUBJECT$ @PREDICAT$ biosynthetic @OBJECT$ has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction. |
Fact | preserve | 1612-1614 | 1612-1614 | T96 | in | ASSOCIATED_WITH | 1,612 | 1,614 | preserve | 1547-1565 | 1558-1565 | T91 | GH binding protein | AminoAcidPeptideOrProtein | 1,547 | 1,565 | preserve | 1621-1628 | 1621-1628 | T95 | obesity | DiseaseOrSyndrome | 1,621 | 1,628 | A9 | As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have been described in obesity. | 1340-1629 | 1,340 | 1,629 | As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased @SUBJECT$ (GHBP) circulating levels have been described @PREDICAT$ @OBJECT$ . |
Fact | preserve | 157-171 | 163-171 | T22 | obese patients | PROCESS_OF | 157 | 171 | preserve | 157-162 | 157-162 | T9 | obese | DiseaseOrSyndrome | 157 | 162 | preserve | 163-171 | 163-171 | T10 | patients | PatientOrDisabledGroup | 163 | 171 | A11 | In fact obese patients display, compared to normal weight subjects, a reduced half-life, frequency of secretory episodes and daily production rate of the hormone. | 149-323 | 149 | 323 | In fact @SUBJECT$ @PREDICAT$ @OBJECT$ display, compared to normal weight subjects, a reduced half-life, frequency of secretory episodes and daily production rate of the hormone. |
Possible | preserve | 3456-3463 | 3456-3463 | T208 | therapy | TREATS | 3,456 | 3,463 | preserve | 3389-3391 | 3389-3391 | T203 | GH | AminoAcidPeptideOrProtein | 3,389 | 3,391 | preserve | 3467-3474 | 3467-3474 | T207 | obesity | DiseaseOrSyndrome | 3,467 | 3,474 | A12 | GH and conceivably GHRPs might therefore have a place in the therapy of obesity. | 3389-3475 | 3,389 | 3,475 | @SUBJECT$ and conceivably GHRPs might therefore have a place in the @PREDICAT$ of @OBJECT$ . |
Uncommitted | preserve | 15-17 | 15-17 | T3 | in | ASSOCIATED_WITH | 15 | 17 | preserve | 0-14 | 7-14 | T1 | Growth hormone | AminoAcidPeptideOrProtein | 0 | 14 | preserve | 18-25 | 18-25 | T2 | obesity | DiseaseOrSyndrome | 18 | 25 | A15 | Growth hormone in obesity. | 0-26 | 0 | 26 | @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 346-373 | 364-373 | T39 | patients GH secretion | PROCESS_OF | 346 | 373 | preserve | 355-373 | 364-373 | T24 | GH secretion | CellFunction | 355 | 373 | preserve | 346-354 | 346-354 | T23 | patients | PatientOrDisabledGroup | 346 | 354 | A16 | Furthermore, in these patients GH secretion is impaired in response to all traditional pharmacological stimuli acting at the hypothalamus (insulin-induced hypoglycaemia, arginine, galanin, L-dopa, clonidine, acute glucocorticoid administration) and to direct somatotrope stimulation by exogenous growth hormone releasing hormone (GHRH). | 324-684 | 324 | 684 | Furthermore, in these @OBJECT$ @PREDICAT$ @SUBJECT$ is impaired in response to all traditional pharmacological stimuli acting at the hypothalamus (insulin-induced hypoglycaemia, arginine, galanin, L-dopa, clonidine, acute glucocorticoid administration) and to direct somatotrope stimulation by exogenous growth hormone releasing hormone (GHRH). |
Fact | preserve | 1870-1889 | 1882-1889 | T121 | human obesity | PROCESS_OF | 1,870 | 1,889 | preserve | 1882-1889 | 1882-1889 | T115 | obesity | DiseaseOrSyndrome | 1,882 | 1,889 | preserve | 1870-1875 | 1870-1875 | T114 | human | Human | 1,870 | 1,875 | A17 | Recent evidence suggests that leptin, the product of adipocyte specific ob gene, exerts a stimulating effect on GH release in rodents; should the same hold true in man, the coexistence of high leptin and low GH serum levels in human obesity would fit in well with the concept of a leptin resistance in this condition. | 1630-1972 | 1,630 | 1,972 | Recent evidence suggests that leptin, the product of adipocyte specific ob gene, exerts a stimulating effect on GH release in rodents; should the same hold true in man, the coexistence of high leptin and low GH serum levels in @OBJECT$ @PREDICAT$ @SUBJECT$ would fit in well with the concept of a leptin resistance in this condition. |
Fact | preserve | 3323-3337 | 3329-3337 | T202 | obese patients | PROCESS_OF | 3,323 | 3,337 | preserve | 3323-3328 | 3323-3328 | T196 | obese | DiseaseOrSyndrome | 3,323 | 3,328 | preserve | 3329-3337 | 3329-3337 | T197 | patients | PatientOrDisabledGroup | 3,329 | 3,337 | A19 | In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction. | 3167-3388 | 3,167 | 3,388 | In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in @SUBJECT$ @PREDICAT$ @OBJECT$ undergoing therapeutic severe caloric restriction. |
Fact | preserve | 2366-2368 | 2366-2368 | T150 | in | ASSOCIATED_WITH | 2,366 | 2,368 | preserve | 2343-2355 | 2343-2355 | T143 | somatotropin | AminoAcidPeptideOrProtein | 2,343 | 2,355 | preserve | 2369-2376 | 2369-2376 | T145 | obesity | DiseaseOrSyndrome | 2,369 | 2,376 | A20 | Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity. | 1973-2377 | 1,973 | 2,377 | Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve @SUBJECT$ secretion @PREDICAT$ @OBJECT$ . |
Fact | preserve | 2196-2209 | 2202-2209 | T146 | obese patient | PROCESS_OF | 2,196 | 2,209 | preserve | 2196-2201 | 2196-2201 | T132 | obese | DiseaseOrSyndrome | 2,196 | 2,201 | preserve | 2202-2209 | 2202-2209 | T133 | patient | PatientOrDisabledGroup | 2,202 | 2,209 | A2 | Our data suggest that laparoscopic renal and adrenal surgery is technically feasible in the markedly and morbidly obese patient, and compared with open surgery results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay. | 2075-2417 | 2,075 | 2,417 | Our data suggest that laparoscopic renal and adrenal surgery is technically feasible in the markedly and morbidly @SUBJECT$ @PREDICAT$ @OBJECT$ , and compared with open surgery results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay. |
Fact | preserve | 1046-1074 | 1066-1074 | T76 | inferior vena caval thrombus | LOCATION_OF | 1,046 | 1,074 | preserve | 1046-1065 | 1060-1065 | T71 | inferior vena caval | BodyLocationOrRegion | 1,046 | 1,065 | preserve | 1066-1074 | 1066-1074 | T72 | thrombus | DiseaseOrSyndrome | 1,066 | 1,074 | A4 | Open group patients with factors precluding laparoscopic surgery were excluded from the study (mass greater than 10 cm., renal vein and/or inferior vena caval thrombus and extension outside Gerota's fascia). | 895-1120 | 895 | 1,120 | Open group patients with factors precluding laparoscopic surgery were excluded from the study (mass greater than 10 cm., renal vein and/or @SUBJECT$ @PREDICAT$ @OBJECT$ and extension outside Gerota's fascia). |
Fact | preserve | 1972-1986 | 1978-1986 | T125 | obese patients | PROCESS_OF | 1,972 | 1,986 | preserve | 1972-1977 | 1972-1977 | T118 | obese | DiseaseOrSyndrome | 1,972 | 1,977 | preserve | 1978-1986 | 1978-1986 | T119 | patients | PatientOrDisabledGroup | 1,978 | 1,986 | A5 | CONCLUSIONS: Markedly obese patients have an increased risk of complications from surgery, regardless of the approach. | 1944-2074 | 1,944 | 2,074 | CONCLUSIONS: Markedly @SUBJECT$ @PREDICAT$ @OBJECT$ have an increased risk of complications from surgery, regardless of the approach. |
Fact | preserve | 210-224 | 216-224 | T20 | obese patients | PROCESS_OF | 210 | 224 | preserve | 210-215 | 210-215 | T17 | obese | DiseaseOrSyndrome | 210 | 215 | preserve | 216-224 | 216-224 | T18 | patients | PatientOrDisabledGroup | 216 | 224 | A6 | PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open surgery in obese patients are unknown. | 92-237 | 92 | 237 | PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open surgery in @SUBJECT$ @PREDICAT$ @OBJECT$ are unknown. |